Our group has been investigating design and syntheses of N-methyl-D-aspartate receptor (NMDAR) antagonists as possible neuroprotective agents.  Such compounds can be useful in the treatment of various disorders including epilepsy, Alzheimer's disease and neuropathic pain.  Previous efforts by our group have confirmed 2-arylnorbornan-2-amines to be significant micromolar antagonists in vitro.  These compounds have also displayed anticonvulsant activities in vivo.  However, the compounds are racemic.  Four diastereomers are possible for each compound.  Stereoselective synthetic as well as resolution schemes have been devised to yield each enantiomer of target compounds starting with commercially available norcamphor.  Grignard reaction gave racemic alcohol which was converted into diastereomers and separated.  Target compounds resulting from such intermediates can help shed light on the pharmacophore for binding on NMDAR.

Norcamphor based NMDA receptor antagonists

244th National Meeting (2012)

The official archive and repository for all ACS Meetings & Expositions abstracts and select posters or presentations.